The UHM Vacation IPO subscription opened on June 4, 2026, and will close on June…
Bio Medica Laboratories IPO Subscription Status Day-2: Live Bidding
Bio Medica Laboratories IPO subscription opened on Thursday, May 21, 2026 and will remain open until May 25, 2026. The company aims to raise around ₹52.43 crores through the IPO issue. The allocation structure includes 35% reserved for retail investors, 50% for QIBs, and 15% for NII investors. The Bio Medica Laboratories IPO price band has been fixed at ₹132 to ₹139 per equity share.
The minimum market lot for the Bio Medica Laboratories IPO is 2,000 shares with an application amount of ₹2,78,000. The issue is categorized as an SME IPO and is proposed to be listed on NSE SME.
Bio Medica Laboratories IPO Subscription Status – Day 2
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 11.97 | 15.94 | 0.00 |
| NII | 0.02 | 0.02 | 0.00 |
| RII | 0.86 | 1.21 | 0.00 |
| Total | 0.56 | 0.77 | 0.00 |
About Company
BIO MEDICA LABORATORIES LIMITED is a leading parenteral manufacturing company based in Central India, known for its strong focus on quality, innovation, and healthcare excellence. The company specializes in producing a wide range of parenteral formulations, including injectables for human and veterinary applications. Built on a foundation of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), BIO MEDICA ensures that every product meets strict international standards of safety, purity, and effectiveness. Its modern manufacturing facilities are equipped with advanced technology, enabling consistent production of high-quality injectable solutions for domestic as well as global markets.
The company offers a diverse portfolio of injectable products designed to meet the needs of hospitals, healthcare providers, and veterinary care sectors. With a growing export presence, BIO MEDICA LABORATORIES LIMITED continues to expand its global footprint by delivering reliable healthcare solutions worldwide. The organization is driven by a strong mission to improve health and well-being through innovative parenteral formulations for both humans and animals. Its vision is to become a globally recognized leader in the pharmaceutical manufacturing industry by maintaining excellence, sustainability, and continuous improvement in all aspects of its operations.
Related Posts
